BiondVax meets with BARDA about universal flu vaccine
BARDA invited BiondVax to present on clinical trial results for Multimeric 001 to the authority's influenza division. BARDA told BiondVax that the authority will consider proposals to supply the U.S. with pandemic vaccines while funding clinical trials that examine M-001 as a primer to provide preparedness ahead of pandemic flu vaccines.
BiondVax also discussed the use of its vaccine candidate as a standalone universal flu vaccine.
"The U.S. is a key market for influenza vaccines and so it is critical to BiondVax's success that our development strategy reflects the needs of U.S. stakeholders, such as BARDA," Ron Babecoff, the CEO of BiondVax, said. "The U.S. health authorities have a major impact on the global health system and sets the agenda and the level of global preparedness for pandemic outbreaks. We continue to work in parallel with regulatory bodies and health authorities around the world to promote agreements with governments for licensing the universal flu vaccine."
In clinical trials, M-001 demonstrated an excellent safety profile, triggered cellular and humoral immune defenses and stayed active without the need for an adjuvant. BiondVax said the vaccine can be easily, quickly and cheaply manufactured in six to eight weeks.
BARDA's influenza division is considered a world expert on pandemic preparedness and the deliberation of national governments when it comes to the evaluation of medical countermeasures.